Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ1D9A)

Drug Name
4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID Drug Info
Synonyms
5731-10-2; 4-(4-Fluorophenyl)benzoic acid; 4'-Fluoro-biphenyl-4-carboxylic acid; 4'-fluorobiphenyl-4-carboxylic acid; 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID; 4'-Fluoro-biphenyl-4-carboxylic aci; 4'-Fluoro-[1,1'-biphenyl]-4-carboxylic acid; CHEMBL106708; MFCD01631909; 4-(4-Fluorophenyl)benzoic acid, 97%; 4'-fluoro[1,1'-biphenyl]-4-carboxylic acid; 4FC; 4'-fluoro(1,1'-biphenyl)-4-carboxylic acid; 1ysg; 4-Biphenyl-4'-fluoro-carboxylicacid; 4-Biphenyl-4'-fluoro-carboxylic acid; PubChem10277; 1,5-dibenzoyloxybenzene
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2782689
CAS Number
CAS 5731-10-2
TTD Drug ID
DMQ1D9A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Apoptosis regulator Bcl-xL (BCL-xL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-263 DMNE56X Myelofibrosis 2A20.2 Phase 3 [2]
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
APG-1252 DM8O3R9 Small-cell lung cancer 2C25.Y Phase 1/2 [4]
AZD0466 DMWLZI6 Hematologic tumour 2B33.Y Phase 1/2 [5]
PMID27744724-Compound-18 DM73S2C N. A. N. A. Patented [6]
Indole-based analog 2 DM0NEVC N. A. N. A. Patented [6]
PMID27744724-Compound-10 DMFKS2P N. A. N. A. Patented [6]
PMID27744724-Compound-21 DM18UA5 N. A. N. A. Patented [6]
Indole-based analog 3 DMTEYQJ N. A. N. A. Patented [6]
PMID27744724-Compound-26 DM8GOH3 N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis regulator Bcl-xL (BCL-xL) TTU1E82 B2CL1_HUMAN Inhibitor [1]

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 Clinical pipeline report, company report or official report of Roche (2009).
3 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
4 Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
5 Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
6 Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.